Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 4/2020

01-04-2020 | Hepatitis C | Concise Research Report

The Cost of Hepatitis C Testing Strategies in Primary Care Patients with Abnormal Transaminases

Authors: Andrew D. Schreiner, MD, MSCR, Don C. Rockey, MD, William P. Moran, MD

Published in: Journal of General Internal Medicine | Issue 4/2020

Login to get access

Excerpt

Hepatitis C virus antibody (HCV Ab) testing of patients born between 1945 and 1965 has dramatically improved HCV diagnosis in primary care.1 HCV Ab tests are highly sensitive, widely available, and low cost, but require confirmation with HCV RNA when positive. HCV Ab testing is the most cost-effective strategy for screening birth cohort (1945–1965) patients given their anti-HCV prevalence of 3.25%.2 Abnormal alanine and aspartate aminotransferases (ALT and AST) are another indication for HCV testing, but with higher anti-HCV prevalence, the most cost-effective strategy for testing patients with these lab findings is not clear.3 …
Literature
1.
Barocas JA, Wang J, White LF, et al. Hepatitis C Testing Increased Among Baby Boomers Following The 2012 Change To CDC Testing Recommendations. Health Aff (Millwood). 2017;36(12):2142–2150.CrossRef
2.
Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157(11):817–822.CrossRef
3.
Smith BD, Yartel AK. Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels. Am J Prev Med. 2014;47(3):233–241.CrossRef
4.
Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG. Cost-effectiveness of strategies for testing current hepatitis C virus infection. Hepatology (Baltimore, Md) 2015;62(5):1396–1404.CrossRef
5.
Services CfMM. CY 2019 Q1 Release: Revised for January 2019. 2019.
Metadata
Title
The Cost of Hepatitis C Testing Strategies in Primary Care Patients with Abnormal Transaminases
Authors
Andrew D. Schreiner, MD, MSCR
Don C. Rockey, MD
William P. Moran, MD
Publication date
01-04-2020
Publisher
Springer International Publishing
Keyword
Hepatitis C
Published in
Journal of General Internal Medicine / Issue 4/2020
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05250-w

Other articles of this Issue 4/2020

Journal of General Internal Medicine 4/2020 Go to the issue

Original Research

The Mindful Manager: Validation of a Rounding Leadership Instrument for Residents

Original Research

Development and Establishment of Initial Validity Evidence for a Novel Tool for Assessing Trainee Admission Notes

Concise Research Report

Disclosure of Article Funding and Conflicts of Interest in High-Impact Clinical Journals

Original Research

Cost-effectiveness of Practice Team-Supported Exposure Training for Panic Disorder and Agoraphobia in Primary Care: a Cluster-Randomized Trial

Original Research

Differences in Rates of High-Value and Low-Value Care Between Community Health Centers and Private Practices

Original Research

Too Many Don’ts and Not Enough Do’s? A Survey of Hospitals About Their Portal Instructions for Patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits